Advertisement Amneal releases Felbamate Oral Suspension - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Amneal releases Felbamate Oral Suspension

Amneal Pharmaceuticals has released the first generic Felbamate oral suspension in 600 mg/5 mL strength.

The AB-rated product is a therapeutically equivalent alternative to the antiepileptic Felbatol (a registered trademark of Meda Pharmaceuticals).

The Amneal generic is available in two sizes, 8 fl oz/240 mL and 16 fl oz/473 mL.

The pink, bubble gum-flavored liquid does not require refrigeration and is manufactured in Amneal’s cGMP-compliant plant in New Jersey, the company said.

Amneal president Chirag Patel said the FDA nod would help in the expansion of their liquids portfolio.

"Additionally, by bringing another first-to-market generic to the public, we are reinforcing our commitment to provide pharmacy customers and the consumer with high-quality, affordable pharmaceuticals," Patel added.

The US FDA has approved Amneal’s ANDA for Felbamate oral suspension on 16 December 2011.